First Time Loading...
R

Ryvu Therapeutics SA
WSE:RVU

Watchlist Manager
Ryvu Therapeutics SA
WSE:RVU
Watchlist
Price: 58.3 PLN -1.19% Market Closed
Updated: Mar 5, 2024

Wall Street
Price Targets

RVU Price Targets Summary
Ryvu Therapeutics SA

Wall Street analysts forecast RVU stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RVU is 72.59 PLN with a low forecast of 69.19 PLN and a high forecast of 78.75 PLN.

Lowest
Price Target
69.19 PLN
19% Upside
Average
Price Target
72.59 PLN
25% Upside
Highest
Price Target
78.75 PLN
35% Upside
Ryvu Therapeutics SA Competitors:
Price Targets
ADPT
Adaptive Biotechnologies Corp
69% Upside
038290
Macrogen Inc
84% Upside
LONN
Lonza Group AG
7% Upside
MEDP
Medpace Holdings Inc
5% Upside
OLK
Olink Holding AB (publ)
15% Upside
AZTA
Azenta Inc
11% Upside
DCAL
Dishman Carbogen Amcis Ltd
40% Downside
ALIF B
AddLife AB
44% Upside

Revenue
Forecast

Revenue Estimate
Ryvu Therapeutics SA

For the last 8 years the compound annual growth rate for Ryvu Therapeutics SA's revenue is 4%. The projected CAGR for the next 3 years is 116%.

4%
Past Growth
116%
Estimated Growth
Estimates Accuracy
-36%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Ryvu Therapeutics SA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Net Income
Forecast

Net Income Estimate
Ryvu Therapeutics SA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-47%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is RVU's stock price target?
Price Target
72.59 PLN

According to Wall Street analysts, the average 1-year price target for RVU is 72.59 PLN with a low forecast of 69.19 PLN and a high forecast of 78.75 PLN.

What is Ryvu Therapeutics SA's Revenue forecast?
Projected CAGR
116%

For the last 8 years the compound annual growth rate for Ryvu Therapeutics SA's revenue is 4%. The projected CAGR for the next 3 years is 116%.